Risk Reduced Drug Development

SynDevRx™, Inc. is developing novel polymeric nanomedicines that inhibit an enzyme which regulates proteins and signaling pathways key to cell growth and survival.  Inhibiting this activity is expected to provide therapeutic benefit in many diseases including,

   •   cancer,

   •   rheumatoid arthritis

   •   endometriosis

   •   AMD and diabetic retinopathy

   •   inflammation diseases including COPD, IPF, and

   •   IL2 induced edema.

Technical risk is reduced since functional parts of our polymeric nanomedicines are well characterized with many years of supportive research.  The active ingredient has clinically demonstrated anti-tumor activity in many tumor types including non-small cell lung, metastatic breast, ovarian, cervical, colon, melanoma, among others. Patents have recently issued covering the core elements of our program.

Based on our timeline, we expect to be in clinical trials in 18 months with our lead drug.